Based on the DESTINY-PanTumor02 phase II trial (31), trastuzumab deruxtecan showed encouraging antitumor activity in patients with HER2 IHC 1+ or 2+ endometrial and ovarian cancers. The gene discussed is ERBB2; the disease is ovarian carcinoma.